Donate

Latest News

MEDIA RELEASE 2 July 2015

Official Launch of the New Zealand Multiple Sclerosis Research Trust

 

$900,000 in grants kick starts Trust dedicated to New Zealand-based Multiple Sclerosis research

The New Zealand Multiple Sclerosis Research Trust (“NZMSRT”) today announces it has received a combined $900,000 investment portfolio as founding capital for the Trust.

A $600,000 portfolio has been transferred from the Multiple Sclerosis Society of New Zealand and a $300,000 portfolio from the Multiple Sclerosis Auckland Region Trust. The Research Trust has been established to stimulate, co-ordinate and support New Zealand-based research into the cause, prevention, treatment, alleviation and cure of Multiple Sclerosis (MS), and to obtain and disseminate research findings.

NZMSRT Trustee Neil Woodhams said: “We are delighted to have secured this substantial initial funding. This is an important first step to securing much needed capital for the many New Zealand-based MS research projects that need our help. With the Trust now established, we will be looking at further opportunities to increase the capital base of the Trust.”

The Trust has a target of raising a minimum of $5 million in the next 5 years and will use income generated from its investments to collaborate with partners to fund research that improves the lives of people with MS. With the rate of MS on the increase in New Zealand, there is a need to centralise the autonomous research being undertaken by numerous different organisations throughout the country.

“A single point of focus is needed for funding MS research. In the past, in many cases research for MS has been one of only a number of research strands within organisations that deal with a wide range of neurological or other health conditions,” Mr Woodhams said.

Because of its size, geographic spread of population and the ability through the health system to accurately track individuals, New Zealand provides an ideal environment for MS research. Recent research has revealed that the incidence of MS for people living in Otago and Southland is four times that of people living inAuckland or Northland.

According to figures from the 2006 New Zealand National MS Prevalence Study, 2,917 people have been diagnosed with MS in New Zealand with the female to male ratio of illness at 3:1. The number of people with MS has continued to grow since
then due to the number of new cases being diagnosed every year. The Trust is registered under the Charitable Trusts Act.

About New Zealand Multiple Sclerosis Research Trust:

The New Zealand Multiple Sclerosis Research Trust was established for the purpose of stimulating, co-ordinating and supporting New Zealand-based research into the cause, prevention, treatment, alleviation and cure of Multiple Sclerosis (MS), and to obtain and disseminate research findings. Registered under the Charitable Trusts Act, the NZ MS Research Trust collaborates with partners to fund research that helps people with MS, informs people about research findings and uses fact-based research findings to improve the lives of people with MS. See: www.msresearch.nz

 

 

Caption: From left to right, Peter Wood and Graham Wear, Trustees of the Auckland Region MS Trust present NZMS Research Trustees Neil Woodhams and Tim Preston a $300,000 Investment Portfolio to establish funding for the Research Trust. Peter Wood is also a Trustee for NZMSRT.

 

Latest News

The following updates consist of a selection of articles retrieved every week.  The original abstracts to each of the articles can be assessed via the links provided.

 

The Neurology Research Review has published a supplement focussed on Multiple Sclerosis. We would like to thank the Research Review for allowing us to share the supplement.

Download PDF

 

Overview - (taken directly from the supplement)

Our understanding of MS, like many areas of neurology, has undergone a revolution driven by neuroimaging and molecular biology. In this review we discuss new thinking on the diagnosis of MS based on MRI findings, and discuss subtypes of neuroinflammation that we are separating off from MS, particularly neuromyelitis optica (NMO).

 

We will also try to bring some clarity to a wave of exciting, complex and expensive treatments that have appeared for MS that will transform the way we think about and manage the condition.

 

Wallace Brownlee has co-edited this review. Wallace has just finished his NZ training as a neurologist and is about to depart for the UK to take up a fellowship in neuroinflammatory disorders. He is part of a new wave of young neurologists taking an active interest in the management of MS and related disorders.

 

We hope you find this special issue interesting and look forward to hearing your comments.

 

Kind Regards,

 

Barry

 

Dr Barry Snow

 

barrysnow@researchreview.co.nz

 


Medical Professionals can subscribe to the quaterly Review via www.researchreview.co.nz

 

 

 

Receive a weekly update of the latest research news from around the world straight to your email box